tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kakefuda T et al. Nitrosyl hemoglobin detected by near-infrared spectroscopy in rat liver allografts. 1999 Transpl. Int. pmid:10551995
Chen L et al. Bastadin 10 stabilizes the open conformation of the ryanodine-sensitive Ca(2+) channel in an FKBP12-dependent manner. 1999 J. Biol. Chem. pmid:10551814
Zoppo A et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. 1999 Transplantation pmid:10551656
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Rolles K et al. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. 1999 Transplantation pmid:10551650
Ocran KW et al. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation. 1999 Z Gastroenterol pmid:10549098
Dubernard JM et al. [The first transplantation of a hand in humans. Early results]. 1999 Chirurgie pmid:10546388
Klein A Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group. 1999 Liver Transpl Surg pmid:10545538
Himukai R et al. Relationship between the subcellular localization and structures of catalytic domains of FKBP-type PPIases. 1999 J. Biochem. pmid:10544281
Wiedeman PE et al. Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12. 1999 J. Med. Chem. pmid:10543889
Pearlman DA Free energy grids: a practical qualitative application of free energy perturbation to ligand design using the OWFEG method. 1999 J. Med. Chem. pmid:10543875
Aoki Y and Kao PN Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. 1999 Antimicrob. Agents Chemother. pmid:10543746
Matsuda J [Tacrolimus hydrate (tacrolimus)]. 1999 Nippon Rinsho pmid:10543146
Capone D et al. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. 1999 Ann Pharmacother pmid:10534229
Mistríková J et al. Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72). 1999 Viral Immunol. pmid:10532652
Leroy-Matheron C et al. Inhibitor against coagulation factor V after liver transplantation. 1999 Transplantation pmid:10532550
Migita K et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. 1999 Transplantation pmid:10532544
Ellis D et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. 1999 Transplantation pmid:10532541
Morris-Stiff G et al. Immunosuppression in renal transplantation. Meta-analysis should not have included one of the studies. 1999 BMJ pmid:10531121
Minematsu T et al. Sustained QT prolongation induced by tacrolimus in guinea pigs. 1999 Life Sci. pmid:10530807
Okada M et al. Successful treatment of chronic graft-versus-host disease with sulfasalazine in allogeneic bone marrow transplantation. 1999 Acta Haematol. pmid:10529517
Morita H et al. Immunosuppressive effect of leukotriene B(4) receptor antagonist in vitro. 1999 Biochem. Biophys. Res. Commun. pmid:10529362
Cannon RD et al. Clinical efficacy of the Abbott Tacrolimus II assay for the IMx. 1999 Oct-Dec Ann. Clin. Lab. Sci. pmid:10528829
Grimbert P et al. Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient. 1999 Nephrol. Dial. Transplant. pmid:10528682
Shadidy M et al. Biochemical analysis of mouse FKBP60, a novel member of the FKPB family. 1999 Biochim. Biophys. Acta pmid:10524204
Lee SF et al. Cytokine receptor common beta chain as a potential activator of cytokine withdrawal-induced apoptosis. 1999 Mol. Cell. Biol. pmid:10523628
Mao Z and Wiedmann M Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. 1999 J. Biol. Chem. pmid:10521511
Hübner GI et al. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. 1999 Ther Drug Monit pmid:10519451
Yoshimoto T and Siesjö BK Posttreatment with the immunosuppressant cyclosporin A in transient focal ischemia. 1999 Brain Res. pmid:10519051
Pacocha SE et al. Regulation of antigen-induced human T-lymphocyte responses by calcineurin antagonists. 1999 J. Allergy Clin. Immunol. pmid:10518828
Bekersky I et al. Bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design. 1999 J Clin Pharmacol pmid:10516937
Przepiorka D et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. 1999 Bone Marrow Transplant. pmid:10516680
Moore JM NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery. 1999 Biopolymers pmid:10516573
Cardenas ME et al. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. 1999 Clin. Microbiol. Rev. pmid:10515904
Cunningham EB An inositolphosphate-binding immunophilin, IPBP12. 1999 Blood pmid:10515881
Fan L et al. Improved artificial death switches based on caspases and FADD. 1999 Hum. Gene Ther. pmid:10515447
Charney DA et al. Plasma cell-rich acute renal allograft rejection. 1999 Transplantation pmid:10515379
Rostaing L et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. 1999 Clin Transplant pmid:10515221
Robinson BV et al. Optimal dosing of intravenous tacrolimus following pediatric heart transplantation. 1999 J. Heart Lung Transplant. pmid:10512526
Dusting GJ et al. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. 1999 Br. J. Pharmacol. pmid:10510443
Böttiger Y et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. 1999 Br J Clin Pharmacol pmid:10510159
Lee WP and Mathes DW Hand transplantation: pertinent data and future outlook. 1999 J Hand Surg Am pmid:10509267
Sche PP et al. Display cloning: functional identification of natural product receptors using cDNA-phage display. 1999 Chem. Biol. pmid:10508685
Chautan M et al. Interdigital cell death can occur through a necrotic and caspase-independent pathway. 1999 Curr. Biol. pmid:10508592
Tredger JM et al. Performance of the IMx tacrolimus II assay and practical limits of detection. 1999 Clin. Chem. pmid:10508145
Cao Z et al. Comparison of tacrolimus concentrations measured by the IMx tacrolimus II vs the PRO-TRAC II FK506 ELISA assays. 1999 Clin. Chem. pmid:10508139
Cacciarelli TV et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1999 Transplantation pmid:10507484
Letko E et al. Tacrolimus (FK 506). 1999 Ann. Allergy Asthma Immunol. pmid:10507260
Linder MW and Elin RJ Implications of methodologic bias for therapeutic drug monitoring. 1999 Arch. Pathol. Lab. Med. pmid:10506447
Yoshimura R et al. The effect of immunosuppressive agents (FK-506, rapamycin) on renal P450 systems in rat models. 1999 J. Pharm. Pharmacol. pmid:10504034
Abu-Elmagd K et al. Hepatic and intestinal transplantation at the University of Pittsburgh. 1998 Clin Transpl pmid:10503105
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Toki K et al. Histopathologic findings in routine biopsies of renal transplant allografts. 1999 Transplant. Proc. pmid:10500759
Ribas Y et al. Lack of accommodation after long-term survival of hamster xenografts in rats. 1999 Transplant. Proc. pmid:10500752
Escartín A et al. Orthotopic small bowel transplantation in pigs without steroids. 1999 Transplant. Proc. pmid:10500720
Chávez R et al. Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. 1999 Transplant. Proc. pmid:10500655
Bárcena R et al. Immunosuppression in liver transplantation: a European survey. 1999 Transplant. Proc. pmid:10500654
González-Pinto I et al. Usefulness of the switch to tacrolimus in liver transplantation. 1999 Transplant. Proc. pmid:10500653
González MG et al. Comparison of post-liver transplantation electrocardiographic alterations between cyclosporine- and tacrolimus-treated patients. 1999 Transplant. Proc. pmid:10500652
García González M et al. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. 1999 Transplant. Proc. pmid:10500620
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients. 1999 Transplant. Proc. pmid:10500604
Cofan F et al. Fatty acid composition in low-density lipoproteins from renal transplant recipients. 1999 Transplant. Proc. pmid:10500603
Torregrosa JV et al. Combined liver-kidney transplantation: our experience. 1999 Transplant. Proc. pmid:10500591
García Meseguer C et al. The effect of different immunosuppression on the outcome of pediatric renal transplants. 1999 Transplant. Proc. pmid:10500577
Moreno M et al. Clinical management of tacrolimus drug interactions in renal transplant patients. 1999 Transplant. Proc. pmid:10500564
Gómez G et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. 1999 Transplant. Proc. pmid:10500563
Morales E et al. Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid-responsive acute rejection. 1999 Transplant. Proc. pmid:10500562
Shapiro R Tacrolimus in solid organ transplantation: an update. 1999 Transplant. Proc. pmid:10500545
Sengoku T et al. Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models. 1999 Eur. J. Pharmacol. pmid:10497905
Woo KT Current therapeutic strategies in glomerulonephritis. 1999 Ann. Acad. Med. Singap. pmid:10497681
Jain A et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. 1999 Ann. Surg. pmid:10493490
Yeh CN et al. Acute overdoses of tacrolimus (FK 506). 1999 Dig. Dis. Sci. pmid:10492148
Sata M and Walsh K Cyclosporine downregulates Fas ligand expression on vascular endothelial cells: implication for accelerated vasculopathy by immunosuppressive therapy. 1999 Biochem. Biophys. Res. Commun. pmid:10491310
Ahlers C et al. Cyclosporin A inhibits Ca2+-mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells. 1999 Eur. J. Biochem. pmid:10491144
Muthuswamy SK et al. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. 1999 Mol. Cell. Biol. pmid:10490623
Pinna AD et al. Unusual presentation of graft-versus-host disease in pediatric liver transplant recipients: evidence of late and recurrent disease. 1999 Pediatr Transplant pmid:10487286
Tsuji-Takayama K et al. Interleukin-18 induces interferon-gamma production through NF-kappaB and NFAT activation in murine T helper type 1 cells. 1999 Cell. Immunol. pmid:10486154
Otsu S et al. [T cell non-depleted bone marrow transplantation for primary refractory erythroleukemia using a partially HLA-mismatched related donor]. 1999 Rinsho Ketsueki pmid:10483142
Mookerjee B et al. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. 1999 Bone Marrow Transplant. pmid:10482936
Fleischer AB Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. 1999 J. Allergy Clin. Immunol. pmid:10482864
Hodge S et al. Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj. 1999 J. Virol. pmid:10482616
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Fredericks S and Holt DW TGF-beta quantitation can be tricky. 1999 Transplantation pmid:10480399
Chan MA et al. Triptolide is more effective in preventing T cell proliferation and interferon-gamma production than is FK506. 1999 Phytother Res pmid:10479754
Christner C et al. Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties. 1999 J. Med. Chem. pmid:10479292
Perry SS et al. Direct effects of cyclosporin A on proliferation of hematopoietic stem and progenitor cells. 1999 Jul-Aug Cell Transplant pmid:10478713
Herrero JI et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. 1999 Liver Transpl Surg pmid:10477843
Medina J et al. Cytokine profile of human bronchoalveolar macrophages and bronchial epithelial cells in response to inhalation particles of the cyclosporine derivative IMM 125. 1999 Inhal Toxicol pmid:10477442
Hohl CM and Altschuld RA FK506 alters sarcoplasmic reticulum calcium release in neonatal piglet cardiac myocytes. 1999 Pediatr. Res. pmid:10473047
MacFarlane GD et al. Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood. 1999 Clin. Chem. pmid:10471647
Holtbäck U and Eklöf AC Mechanism of FK 506/520 action on rat renal proximal tubular Na+, K+-ATPase activity. 1999 Kidney Int. pmid:10469369
Grassberger M et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. 1999 Br. J. Dermatol. pmid:10468798
Yokogawa K et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. 1999 Pharm. Res. pmid:10468022
Ogino Y et al. Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats. 1999 J. Pharm. Pharmacol. pmid:10467956
Johnson CE and Truong NM Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride. 1999 Jul-Aug J Am Pharm Assoc (Wash) pmid:10467814
Ivery MT A proposed molecular model for the interaction of calcineurin with the cyclosporin A-cyclophilin A complex. 1999 Bioorg. Med. Chem. pmid:10465413
Shuto H et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. 1999 Life Sci. pmid:10465348
Alexanian AR and Bamburg JR Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB. 1999 FASEB J. pmid:10463953
Wandel C et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. 1999 Cancer Res. pmid:10463589
Arndt C et al. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. 1999 Microbiology (Reading, Engl.) pmid:10463165